|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
gptkb:physician
|
|
gptkbp:approvalRegion
|
gptkb:Japan
gptkb:United_States
|
|
gptkbp:approvalYear
|
2023-01-06
|
|
gptkbp:ATCCode
|
N06DX05
|
|
gptkbp:blackBoxWarning
|
yes
|
|
gptkbp:brand
|
gptkb:Leqembi
|
|
gptkbp:CASNumber
|
1800016-26-4
|
|
gptkbp:chemicalFormula
|
C6468H9956N1714O2016S46
|
|
gptkbp:clinicalTrialPhase
|
Phase 3
|
|
gptkbp:contraindication
|
hypersensitivity to lecanemab
|
|
gptkbp:cost
|
$26,500 per year (2023, US)
|
|
gptkbp:developer
|
gptkb:Biogen
gptkb:Eisai
|
|
gptkbp:firstBook
|
no
|
|
gptkbp:genericName
|
gptkb:lecanemab
|
|
gptkbp:halfLife
|
~7 days
|
|
gptkbp:indication
|
gptkb:Alzheimer's_disease
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
anti-amyloid beta monoclonal antibody
|
|
gptkbp:molecularWeight
|
~150 kDa
|
|
gptkbp:patent
|
gptkb:Biogen
gptkb:Eisai
|
|
gptkbp:pregnancyCategory
|
gptkb:unknown
|
|
gptkbp:prescribingPopulation
|
mild cognitive impairment or mild dementia stage of Alzheimer's disease
|
|
gptkbp:prescriptionRequired
|
yes
https://www.leqembi.com/
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:amyloid-related_imaging_abnormalities_(ARIA)
headache
cerebral edema
infusion-related reactions
microhemorrhage
|
|
gptkbp:storage
|
2°C to 8°C
|
|
gptkbp:target
|
gptkb:amyloid_beta_protein
|
|
gptkbp:bfsParent
|
gptkb:Eisai_Co.,_Ltd.
gptkb:Eisai
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Leqembi
|